glp-1 agonists reduce inflammation Health Feed GLP-1 receptor agonists show evidence

In the landmark study for semaglutide, participants were randomized to semaglutide or placebo plus lifestyle interventions

Upcoming catalyst events the order and 6ming of expected GLP-1 and other clinical outcomes in weight loss/obesity to be announced

Drucker provides this illustration of the mechanism: Scientists still arent quite sure how these drugs effectively moderate every system that they touch

[1] Dulaglutide (Trulicity): 0.75 mg or 1.5 mg once weekly for type 2 diabetes

Today, there is still a large number of GLP-1R agonists entering clinical trials, which will lead to a big explosion in the future, so let's wait and see together

The first precursor to Ozempic and Mounjaro came out 20 years ago